Skip to Content

Magenta Therapeutics, Inc.

Merger

  • Date:
  • 5/3/2023
  • Company Name:
  • Magenta Therapeutics, Inc.
  • Stock Symbol:
  • MGTA
  • Company Name - Buyer:
  • Dianthus Therapeutics, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 5/3/2023

Case Finder

Locate any case using the tools below.

NEW YORK, May 3, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Magenta Therapeutics, Inc. (NASDAQ: MGTA) (“Magenta”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Dianthus Therapeutics, Inc. (“Dianthus”).

On May 3, 2023, Magenta announced that it had entered into an agreement to be acquired by Dianthus in an all-stock deal. Pursuant to the merger agreement, pre-merger Dianthus stockholders (including Dianthus stockholders issued shares of Dianthus common stock and pre-funded warrants in the concurrent private financing) are expected to own approximately 78.7% of the combined company and pre-merger Magenta stockholders are expected to own approximately 21.3% of the combined company. The deal is expected to close in the third quarter of 2023.

Bragar Eagel & Squire is concerned that Magenta’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Magenta’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Magenta Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: